PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT02060370: Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
Official title: A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Conditions: Genitourinary Cancer
Kidney Cancer
Summary: The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug. Researchers want to learn more about the side effects of the drug and the effects of a different dosing schedule.
Interventions:
description: Starting dose: 50 mg by mouth daily given for 2 weeks "on" followed by 1 week "off". 1 cycle is 6 weeks.
name: Sunitinib
other_name: SUO11248
Sunitinib Malate
Sutent
type: Drug
description: Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
name: Questionnaire
other_name: Survey
type: Behavioral
Study arms:
design_group_description: Sunitinib starting dose 50 mg by mouth daily given for 2 weeks "on" followed by 1 week "off". 1 cycle is 6 weeks.
design_group_title: Sunitinib
design_group_type: Experimental
Sponsor: The University of Texas MD Anderson Cancer Center
Collaborators: Pfizer Inc.
Drug name mappings:
name: 苹果酸舒尼替尼
lang: CN
name: Sunitinib Malate
lang: EN
name: スニチニブリンゴ酸塩
lang: JP
Clinical trial NCT00446459: Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
Official title: The Highly Sensitized Patients: Effects of Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant
Conditions: Kidney Failure, Chronic
Diabetic Nephropathies
Glomerulonephritis, IGA
Hypertension, Renal
Summary: This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.
On average, increasing the PRA from 0 to 50% specifically in the Washington Organ Procurement Organization (OPO) increases the waiting time from 3 to 6 years. Spontaneous decreases in the PRA rarely occur and is associated with a decreased chance for transplantation and a decreased rate of survival.
Interventions:
description: 500mg - 1,000mg, taken PO, twice daily.
name: mycophenolate mofetil (CellCept)
type: Drug
Study arms:
Sponsor: University of Washington
Collaborators: Hoffmann-La Roche, Inc.
Drug name mappings:
name: 吗替麦考酚酯
lang: CN
name: Mycophenolate Mofetil
lang: EN
name: ミコフェノール酸 モフェチル
lang: JP
Clinical trial NCT00788775: Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Official title: A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma
Conditions: Mucosal Lentiginous Melanoma
Acral Melanoma
Melanoma
Summary: Given the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT mutations in these cancers present the need to test multi-targeted kinase inhibitors with potent KIT inhibitory activity in this patient population. Imatinib and other tyrosine kinase inhibitors (TKIs) have the potential to be effective in this patient population, but patients may develop resistance to treatment. Therefore, in this study, we propose to test nilotinib in patients with metastatic mucosal, acral, or chronically sun-damaged melanoma following treatment with another TKI.
Interventions:
name: Nilotinib
other_name: AMN107
Tasigna
type: Drug
Study arms:
design_group_description: Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit.
design_group_title: Nilotinib
design_group_type: Experimental
Sponsor: Dana-Farber Cancer Institute, Inc.
Collaborators: The Brigham & Women's Hospital, Inc.
The General Hospital Corp.
Novartis AG
Beth Israel Deaconess Medical Center, Inc.
Drug name mappings:
name: 尼洛替尼
lang: CN
name: Nilotinib Hydrochloride
lang: EN
name: ニロチニブ塩酸塩水和物
lang: JP
Clinical trial NCT00215137: Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder
Official title: Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder
Conditions: OCD
Summary: This study will determine the safety and effectiveness of escitalopram (Lexapro)in treating obsessive-compulsive disorder (OCD) symptoms.
Interventions:
description: Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
name: escitalopram
other_name: Lexapro
type: Drug
description: Placebo Comparator in double.blind phase.
name: Placebo ( sugar pill)
other_name: Placebo
type: Drug
Study arms:
design_group_description: Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.
design_group_title: Open Label Escitalopram 10-20 mg/daily
design_group_type: Experimental
design_group_description: Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
design_group_title: Randomizationn Placebo 10-20 mg daily
design_group_type: Placebo Comparator
design_group_description: Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
design_group_title: Randomization Escitalopram 10-20 mg/daily
design_group_type: Active Comparator
Sponsor: Duke University
Collaborators: Forest Laboratories LLC
Drug name mappings:
name: 草酸艾司西酞普兰
lang: CN
name: Escitalopram Oxalate
lang: EN
name: エスシタロプラムシュウ酸塩
lang: JP
Clinical trial NCT02794766: Inulin and S. Salivarius Reduce Halitosis
Official title: Inulin and Streptococcus Salivarius Reduce Halitosis Associated With Tongue Coating: A Randomized Clinical Trial
Conditions: Halitosis
Tongue Diseases
Summary: Halitosis associated with tongue coating results from the production of volatile sulfur compounds by bacterial action. The use of prebiotics and probiotics might be useful in treating such condition. The aim of this study was to evaluate the effect of the prebiotic inulin combined with the probiotic Streptococcus salivarius (SS) on halitosis by coating.
Interventions:
description: Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
name: Inulin+SS
other_name: Inulin plus Streptococcus salivarius
type: Drug
description: Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
name: S salivarius
other_name: Streptococcus salivarius
type: Drug
description: Placebo 1 gum each 12 hours for 10 days
name: Placebo
type: Drug
Study arms:
design_group_description: Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
design_group_title: Inulin+SS
design_group_type: Experimental
design_group_description: Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
design_group_title: S salivarius
design_group_type: Active Comparator
design_group_description: Placebo 1 gum per oral each 12 hours, for 10 days
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: University of Passo Fundo
Collaborators: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Drug name mappings:
name: 菊糖
lang: CN
name: Inulin
lang: EN
name: イヌリン
lang: JP
Clinical trial NCT00006244: Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Official title: Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma
Conditions: Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Summary: This phase II trial studies the effectiveness of melphalan, peripheral stem cell transplantation, and interleukin-2 followed by interferon alfa in treating patients who have advanced multiple myeloma (MM). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Interleukin-2 (IL2) may stimulate a person's white blood cells to kill multiple myeloma cells. Interferon alfa may interfere with the growth of cancer cells
Interventions:
description: Given IV
name: melphalan
other_name: Alkeran
CB-3025
L-PAM
L-Sarcolysin
L-phenylalanine mustard
type: Drug
description: Given SC
name: recombinant interferon alfa
other_name: Alferon N
IFN-A
Intron A
Roferon-A
alpha interferon
type: Biological
description: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
name: aldesleukin
other_name: IL-2
Proleukin
recombinant human interleukin-2
recombinant interleukin-2
type: Biological
description: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
name: in vitro-treated peripheral blood stem cell transplantation
other_name: PBPC transplantation, in vitro-treated
in vitro-treated PBPC transplantation
in vitro-treated PBSC
in vitro-treated peripheral blood progenitor cell transplantation
peripheral blood progenitor cell transplantation, in vitro-treated
type: Procedure
Study arms:
design_group_description: Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.
design_group_title: Treatment (immunotherapy)
design_group_type: Experimental
Sponsor: Fred Hutchinson Cancer Research Center
Collaborators: National Cancer Institute
Drug name mappings:
name: 美法仑
lang: CN
name: Melphalan
lang: EN
name: メルファラン
lang: JP
name: 阿地白介素
lang: CN
name: Aldesleukin
lang: EN
Clinical trial NCT01942837: Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Official title: Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing
Conditions: Metastatic Castration-resistant Prostate Cancer
Summary: This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with chemotherapy.
The purpose of this study is to analyze features of tumor specimens sampled prior to therapy and at disease progression to determine why patients respond or stop responding to treatment with Enzalutamide.
Prior chemotherapy is not a requirement of this trial.
Interventions:
description: Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.
name: Enzalutamide
other_name: Xtandi
type: Drug
Study arms:
design_group_description: Administration: 160 mg orally once daily with a 28-day cycle. Treatment will be continued until evidence of symptomatic or radiographic progression or the participant is taken off the study for another reason.<br/>Dosing: 160 mg orally taken once daily as four 40 mg capsules.
design_group_title: Enzalutamide
design_group_type: Experimental
Sponsor: Dana-Farber Cancer Institute, Inc.
Collaborators: MediVation, Inc.
Drug name mappings:
name: 恩扎卢胺
lang: CN
name: Enzalutamide
lang: EN
name: エンザルタミド
lang: JP
Clinical trial NCT00620568: Study Evaluating Multiple Ascending Dose in Schizophrenia Patients
Official title: An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder
Conditions: Healthy
Summary: This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.
Interventions:
description: sustained release tablets taken once daily for 14 days
name: SLV-313 SR
type: Drug
Study arms:
design_group_title: 1
design_group_type: Experimental
design_group_title: 2
design_group_type: Experimental
design_group_title: 3
design_group_type: Experimental
design_group_title: 4
design_group_type: Experimental
Sponsor: Wyeth AB
Collaborators: Solvay Pharmaceuticals, Inc.
Drug name mappings:
name: 盐酸阿哆嗪
lang: CN
name: Adoprazine Hydrochloride
lang: EN
Clinical trial NCT06557785: A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
Official title: A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
Conditions: HIV Infections
Summary: This is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred to as mRNA-LNPs). The primary hypotheses are:
1. the CH505M5 N197D mRNA-gp160 will expand CH235-like B cell precursors,
2. the CH505 TF mRNA-gp160 will boost CH235-like bnAb B cell precursors to acquire more functional mutations needed for broadly neutralizing antibody (bnAb) development, and
3. these mRNA-LNPs will be safe and well tolerated among individuals living without HIV.
Interventions:
description: To be administered intramuscularly as a split dose
name: CH505M5 N197D mRNA-gp160
type: Biological
description: To be administered intramuscularly as a split dose
name: CH505 TF mRNA-gp160
type: Biological
Study arms:
design_group_description: 25 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16.<br/>Followed by:<br/>25 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24.
design_group_title: Group 1 (25 mcg)
design_group_type: Experimental
design_group_description: 50 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16.<br/>Followed by:<br/>50 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24.
design_group_title: Group 2 (50 mcg)
design_group_type: Experimental
design_group_description: 100 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16.<br/>Followed by:<br/>100 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24.
design_group_title: Group 3 (100 mcg)
design_group_type: Experimental
design_group_description: 150 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16.<br/>Followed by:<br/>150 mcg CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24.
design_group_title: Group 4 (150 mcg)
design_group_type: Experimental
Sponsor: National Institute of Allergy & Infectious Diseases
Collaborators: Tasmania Department of Health & Human Services
National Institutes of Health
Drug name mappings:
name: CH505 TF mRNA-gp160
lang: EN
name: CH505M5 N197D mRNA-gp160
lang: EN
Clinical trial NCT00788112: Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
Official title: A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast
Conditions: Breast Cancer
Summary: RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast.
Interventions:
name: vorinostat
type: Drug
name: protein expression analysis
type: Genetic
name: immunohistochemistry staining method
type: Other
name: laboratory biomarker analysis
type: Other
name: neoadjuvant therapy
type: Procedure
name: therapeutic conventional surgery
type: Procedure
Study arms:
design_group_title: Vorinostat
design_group_type: Experimental
Sponsor: The University of California, San Francisco
Collaborators: National Cancer Institute
Drug name mappings:
name: 伏立诺他
lang: CN
name: Vorinostat
lang: EN
name: ボリノスタット
lang: JP
Clinical trial NCT03300505: ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Official title: ARRO-CITO: (UMCC 2017.055) Phase Ib/II Single-Arm Multi-Center Study of IONIS-AR-2.5Rx, a Next Generation Androgen Receptor Antisense Oligonucleotide, in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Conditions: Prostate Cancer
Summary: The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of ARRx (also known as AZD5312) plus enzalutamide in patients with metastatic castration resistant prostate cancer.
Interventions:
description: Given intravenously (IV)
name: ARRx
other_name: AZD5312
type: Drug
description: Given by mouth (PO)
name: Enzalutamide
other_name: Xtandi
type: Drug
Study arms:
design_group_description: Phase 1b: All registered subjects will be treated with ARRx (ASO) in combination with enzalutamide. ARRx will be given intravenously on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1, 8, 15 in subsequent 21-day cycles. Enzalutamide will be taken daily in 21 day cycles starting Day 1 of cycle 1. Treatment will continue until clinical or radiologic progression or unacceptable toxicity.<br/>Phase 2: Subjects will be treated with ARRx (ASO) at the maximum tolerated (MTD), in combination with enzalutamide until clinical or radiologic progression or unacceptable toxicity. (Schedule of administration as in phase 1b.)
design_group_title: ARRx + Enzalutamide
design_group_type: Experimental
Sponsor: Rogel Cancer Center: University of Michigan
Collaborators: National Cancer Institute
Drug name mappings:
name: 恩扎卢胺
lang: CN
name: Enzalutamide
lang: EN
name: エンザルタミド
lang: JP
name: AZD-5312
lang: EN
Clinical trial NCT00753844: Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer
Official title: Tumor Vaccine Therapy Against Advanced Esophageal Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10
Conditions: Esophageal Cancer
Summary: The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent esophageal cancer.
Interventions:
description: Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
name: URLC10
type: Biological
Study arms:
Sponsor: Kinki University
Collaborators: University of Tokyo
Drug name mappings:
name: HLA-A*2402 Restricted Epitope Peptides Drived From URLC10 Vaccine(Kinki University)
lang: EN
Clinical trial NCT00667901: Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Official title: A Phase 0 Trial of Riluzole in Patients With Resectable Stage III and IV Melanoma
Conditions: Melanoma (Skin)
Summary: RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma.
PURPOSE: This early phase I trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that can be removed by surgery.
Interventions:
name: riluzole
type: Drug
name: protein expression analysis
type: Genetic
name: reverse transcriptase-polymerase chain reaction
type: Genetic
name: western blotting
type: Genetic
name: immunohistochemistry staining method
type: Other
name: laboratory biomarker analysis
type: Other
name: pharmacological study
type: Other
name: neoadjuvant therapy
type: Procedure
name: therapeutic conventional surgery
type: Procedure
Study arms:
Sponsor: University of Medicine & Dentistry of New Jersey
Collaborators: National Cancer Institute
Drug name mappings:
name: 利鲁唑
lang: CN
name: Riluzole
lang: EN
name: リルゾール
lang: JP
Clinical trial NCT02937844: Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
Official title: A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme
Conditions: Glioblastoma Multiforme
Summary: CAR T cell immunotherapy has achieved great success in CD19+ B-cell malignancies. Whether this new generation of cell-based immunotherapy can be applied to solid tumors remain to be investigated, partly due to hostile immune-suppressive tumor microenvironment which favors tumor growth but not immune system. Signaling pathway of programmed death 1 (PD-1) and its ligand PD-L1 plays an important role in suppressing immune response against tumors. PD-L1 is over-expressed in 88% of glioblastoma.
We constructed a chimeric switch receptor (CSR) containing the extracellular domain of PD1 fused to the transmembrane and cytoplasmic domain of the costimulatory molecule CD28. CSR modified T cells are able to recognize PD-L1-expressing tumor cells and transduce signals to activate T cells, which results in tumor killing. A truncated EGFR (tEGFR) which lacks of the ligand binding domain and cytoplasmic kinase domain of wildtype EGFR is incorporated into the CSR vector and is used for in vivo tracking and ablation of CSR T cells when necessary. This pilot study is to determine the safety and efficacy of autologous CSR T cells in patients with recurrent glioblastoma.
Interventions:
description: Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.
name: Anti-PD-L1 CSR T cells
type: Biological
description: 250 mg/m^2, d1-3
name: Cyclophosphamide
type: Drug
description: 25mg/m^2, d1-3
name: Fludarabine
type: Drug
Study arms:
design_group_description: Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti- PD-L1 CSR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg.
design_group_title: Anti-PD-L1 CSR T cells
design_group_type: Experimental
Sponsor: Beijing Sanbo Brain Hospital Co., Ltd.
Collaborators: Beijing Mali Biotechnology Co Ltd
Drug name mappings:
name: Anti-PDL1 chimeric switch receptor modified T-cell therapy (Marino Biotechnology)
lang: EN
name: 磷酸氟达拉滨
lang: CN
name: Fludarabine Phosphate
lang: EN
name: フルダラビンリン酸エステル
lang: JP
name: 环磷酰胺
lang: CN
name: Cyclophosphamide
lang: EN
name: シクロホスファミド水和物
lang: JP